Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;140(3):208-221.
doi: 10.1182/blood.2021012249.

Cellular therapies for the treatment and prevention of SARS-CoV-2 infection

Susan R Conway  1   2   3 , Michael D Keller  1   3   4   5 , Catherine M Bollard  1   3   5   6
Affiliations

Cellular therapies for the treatment and prevention of SARS-CoV-2 infection

Susan R Conway et al. Blood. .

Abstract

Patients with blood disorders who are immune suppressed are at increased risk for infection with severe acute respiratory syndrome coronavirus 2. Sequelae of infection can include severe respiratory disease and/or prolonged duration of viral shedding. Cellular therapies may protect these vulnerable patients by providing antiviral cellular immunity and/or immune modulation. In this recent review of the field, phase 1/2 trials evaluating adoptive cellular therapies with virus-specific T cells or natural killer cells are described along with trials evaluating the safety, feasibility, and preliminary efficacy of immune modulating cellular therapies including regulatory T cells and mesenchymal stromal cells. In addition, the immunologic basis for these therapies is discussed.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Classification of cellular therapies for SARS-CoV-2 infection. Cellular therapy for SARS-CoV-2 can be classified as adoptive anti-viral immunotherapy with CST or NK cells to aid immunocompromised patients with viral clearance (A) or immunomodulatory immunotherapy with Tregs or MSCs to correct dysregulated immune responses in patients with severe COVID-19 (B).
See this image and copyright information in PMC

References

    1. Dai M, Liu D, Liu M, et al. . Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-791. - PMC - PubMed
    1. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24(1):179. - PMC - PubMed
    1. Kuderer NM, Choueiri TK, Shah DP, et al. ; COVID-19 and Cancer Consortium . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. - PMC - PubMed
    1. Sharma A, Bhatt NS, St Martin A, et al. . Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e193. - PMC - PubMed
    1. Shah GL, DeWolf S, Lee YJ, et al. . Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020; 130(12):6656-6667. - PMC - PubMed

Publication types

Substances